Subtype
Lung Neuroendocrine Carcinoma
CI-CAN-00003107Explore in graph →
389 active trials6 approved drugs6 evidence items
- NCIt
- C45569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003107Explore in graph →
Clinical trials
1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00259935 | A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT01987232 | Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | AmgenINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00856830 | Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00046111 | A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors | completed | Phase 1 | 1 | GlaxoSmithKlineINDUSTRY | 2 | May 30, 2017 | clinicaltrials |
| NCT01221675 | TF2- Small Cell Lung Cancer Radio Immunotherapy | completed | Phase 1 / Phase 2 | 18 | Centre René GauducheauOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00580320 | Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma | completed | Phase 1 | 17 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01045421 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | completed | Phase 1 / Phase 2 | 273 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00401609 | G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients(G-Step) | completed | Phase 1 / Phase 2 | 85 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00521144 | Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT00346385 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 97 | ImmunoGen, Inc.INDUSTRY | 2 | Mar 26, 2015 | clinicaltrials |
| NCT00544596 | R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00028535 | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00927875 | A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 5 | Bristol-Myers SquibbINDUSTRY | 5 | Jun 3, 2013 | clinicaltrials |
| NCT01079481 | Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 21 | Samsung Medical CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00017251 | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00065429 | Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 64 | ImmunoGen, Inc.INDUSTRY | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00397293 | Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | Ascenta TherapeuticsINDUSTRY | 3 | Aug 24, 2010 | clinicaltrials |
| NCT00423254 | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. | completed | Phase 1 | 12 | Mannkind CorporationINDUSTRY | 1 | Aug 3, 2010 | clinicaltrials |
| NCT00252889 | Doxil Topotecan Doublet Cancer Study | completed | Phase 1 | 20 | Christiana Care Health ServicesOTHER | 1 | Jan 27, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Nov 14, 2017source: clinicaltrials